Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer : results of a phase 3, randomised, placebo-controlled trial.

Smith, Matthew R; Saad, Fred; Coleman, Robert; Shore, Neal; Fizazi, Karim; Tombal, Bertrand; Miller, Kurt; Sieber, Paul; Karsh, Lawrence; Damião, Ronaldo; Tammela, Teuvo L; Egerdie, Blair; Van Poppel, Hendrik; Chin, Joseph; Morote, Juan; Gómez-Veiga, Francisco; Borkowski, Tomasz; Ye, Zhishen; Kupic, Amy; Dansey, Roger

doi:10.1016/S0140-6736(11)61226-9

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer : results of a phase 3, randomised, placebo-controlled trial.

Smith, Matthew R

;

Saad, Fred

;

Coleman, Robert

;

Shore, Neal

;

Goessl, Carsten

;et.al.

(2012) The Lancet — Vol. 379, n° 9810, p. 39-46 (2012)

Files

Smith-2012-Denosumabandbone.pdf

Restricted Access
Adobe PDF
215.97 KB

Request a copy

Details

Authors

Smith, Matthew R
Author
Saad, Fred
Author
Coleman, Robert
Author
Shore, Neal
Author
Tombal, BertrandUCLouvain
Author
Goessl, Carsten
Author

Abstract

Bone metastases are a major cause of morbidity and mortality in men with prostate cancer. Preclinical studies suggest that osteoclast inhibition might prevent bone metastases. We assessed denosumab, a fully human anti-RANKL monoclonal antibody, for prevention of bone metastasis or death in non-metastatic castration-resistant prostate cancer.

Affiliations

Citations

APA
Chicago
FWB

Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damião, R., Tammela, T. L., Egerdie, B., Van Poppel, H., Chin, J., Morote, J., Gómez-Veiga, F., Borkowski, T., Ye, Z., Kupic, A., et al. (2012). Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer : results of a phase 3, randomised, placebo-controlled trial. The Lancet, 379(9810), 39-46. https://doi.org/10.1016/S0140-6736(11)61226-9 (Original work published 2012)